Short Interest in Dogwood Therapeutics, Inc (NASDAQ:DWTX) Drops By 32.3%

Dogwood Therapeutics, Inc (NASDAQ:DWTX) saw a significant decline in short interest in August. As of August 14th, there was short interest totaling 49,958 shares, a decline of 32.3% from the July 30th total of 73,790 shares. Based on an average daily volume of 50,520 shares, the days-to-cover ratio is currently 1.0 days. Currently, 0.1% of the shares of the stock are sold short.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Dogwood Therapeutics stock. Marshall Wace LLP bought a new stake in Dogwood Therapeutics, Inc (NASDAQ:DWTX) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned about 0.51% of Dogwood Therapeutics at the end of the most recent quarter. 9.05% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 target price on shares of Dogwood Therapeutics in a research note on Tuesday, May 19th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Dogwood Therapeutics in a report on Friday, July 24th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Dogwood Therapeutics has an average rating of “Hold” and an average price target of $12.00.

Dogwood Therapeutics Price Performance

Shares of NASDAQ DWTX opened at $2.63 on Wednesday. The stock has a market capitalization of $89.39 million, a P/E ratio of -0.29 and a beta of 1.81. Dogwood Therapeutics has a one year low of $1.28 and a one year high of $9.50. The firm’s 50 day simple moving average is $1.79 and its two-hundred day simple moving average is $1.99.

Dogwood Therapeutics (NASDAQ:DWTX) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.20). As a group, equities analysts expect that Dogwood Therapeutics will post -0.67 earnings per share for the current fiscal year.

About Dogwood Therapeutics

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.